nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP3A4—Temozolomide—melanoma	0.0518	0.385	CbGbCtD
Lisuride—HTR1D—meninx—melanoma	0.05	0.29	CbGeAlD
Lisuride—DRD5—eyelid—melanoma	0.0452	0.263	CbGeAlD
Lisuride—CYP2D6—Vemurafenib—melanoma	0.0446	0.332	CbGbCtD
Lisuride—CYP3A4—Vemurafenib—melanoma	0.0284	0.211	CbGbCtD
Lisuride—CYP3A4—Docetaxel—melanoma	0.00974	0.0724	CbGbCtD
Lisuride—Pulmonary fibrosis—Bleomycin—melanoma	0.00877	0.0446	CcSEcCtD
Lisuride—Pulmonary fibrosis—Carmustine—melanoma	0.00765	0.0389	CcSEcCtD
Lisuride—Pulmonary fibrosis—Temozolomide—melanoma	0.0074	0.0376	CcSEcCtD
Lisuride—HTR2A—hindlimb—melanoma	0.0059	0.0343	CbGeAlD
Lisuride—HTR1B—blood vessel—melanoma	0.00586	0.034	CbGeAlD
Lisuride—HTR1D—blood vessel—melanoma	0.00567	0.0329	CbGeAlD
Lisuride—Pericardial effusion—Docetaxel—melanoma	0.00527	0.0268	CcSEcCtD
Lisuride—HTR2A—appendage—melanoma	0.00506	0.0294	CbGeAlD
Lisuride—Pulmonary fibrosis—Docetaxel—melanoma	0.00492	0.025	CcSEcCtD
Lisuride—Aggression—Bleomycin—melanoma	0.00439	0.0223	CcSEcCtD
Lisuride—Weight decreased—Vemurafenib—melanoma	0.00361	0.0184	CcSEcCtD
Lisuride—Oedema peripheral—Vemurafenib—melanoma	0.00315	0.016	CcSEcCtD
Lisuride—Disorientation—Bleomycin—melanoma	0.00313	0.0159	CcSEcCtD
Lisuride—HTR2A—endothelium—melanoma	0.00305	0.0177	CbGeAlD
Lisuride—DRD3—head—melanoma	0.00305	0.0177	CbGeAlD
Lisuride—HTR1D—eye—melanoma	0.00302	0.0175	CbGeAlD
Lisuride—Cardiac disorder—Vemurafenib—melanoma	0.00297	0.0151	CcSEcCtD
Lisuride—Angiopathy—Vemurafenib—melanoma	0.0029	0.0147	CcSEcCtD
Lisuride—Mediastinal disorder—Vemurafenib—melanoma	0.00288	0.0146	CcSEcCtD
Lisuride—DRD5—head—melanoma	0.00286	0.0166	CbGeAlD
Lisuride—Pleural effusion—Docetaxel—melanoma	0.00283	0.0144	CcSEcCtD
Lisuride—HTR2A—blood vessel—melanoma	0.00282	0.0164	CbGeAlD
Lisuride—Malnutrition—Vemurafenib—melanoma	0.00278	0.0141	CcSEcCtD
Lisuride—HTR2B—skin of body—melanoma	0.00244	0.0142	CbGeAlD
Lisuride—Cough—Vemurafenib—melanoma	0.00243	0.0123	CcSEcCtD
Lisuride—ADRA1B—head—melanoma	0.00234	0.0136	CbGeAlD
Lisuride—ADRA1D—head—melanoma	0.00229	0.0133	CbGeAlD
Lisuride—DRD2—eye—melanoma	0.00227	0.0132	CbGeAlD
Lisuride—Infection—Vemurafenib—melanoma	0.00226	0.0115	CcSEcCtD
Lisuride—DRD2—retina—melanoma	0.00225	0.0131	CbGeAlD
Lisuride—Nervous system disorder—Vemurafenib—melanoma	0.00223	0.0113	CcSEcCtD
Lisuride—Dehydration—Temozolomide—melanoma	0.0022	0.0112	CcSEcCtD
Lisuride—Weight decreased—Bleomycin—melanoma	0.00219	0.0111	CcSEcCtD
Lisuride—DRD1—head—melanoma	0.00218	0.0127	CbGeAlD
Lisuride—Blood pressure increased—Docetaxel—melanoma	0.00216	0.011	CcSEcCtD
Lisuride—HTR2A—neck—melanoma	0.00201	0.0117	CbGeAlD
Lisuride—Decreased appetite—Vemurafenib—melanoma	0.00197	0.01	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vemurafenib—melanoma	0.00196	0.00997	CcSEcCtD
Lisuride—Fatigue—Vemurafenib—melanoma	0.00196	0.00995	CcSEcCtD
Lisuride—Constipation—Vemurafenib—melanoma	0.00194	0.00987	CcSEcCtD
Lisuride—Weight increased—Temozolomide—melanoma	0.00186	0.00944	CcSEcCtD
Lisuride—Weight decreased—Temozolomide—melanoma	0.00185	0.00939	CcSEcCtD
Lisuride—HTR1B—head—melanoma	0.00177	0.0103	CbGeAlD
Lisuride—ADRA2C—mammalian vulva—melanoma	0.00175	0.0102	CbGeAlD
Lisuride—HTR1D—head—melanoma	0.00171	0.00995	CbGeAlD
Lisuride—HTR2C—head—melanoma	0.0017	0.00985	CbGeAlD
Lisuride—Hallucination—Carmustine—melanoma	0.00168	0.00855	CcSEcCtD
Lisuride—Oedema peripheral—Carmustine—melanoma	0.00167	0.00847	CcSEcCtD
Lisuride—ADRB1—head—melanoma	0.00166	0.00967	CbGeAlD
Lisuride—Asthenia—Vemurafenib—melanoma	0.00163	0.00828	CcSEcCtD
Lisuride—Hallucination—Temozolomide—melanoma	0.00163	0.00826	CcSEcCtD
Lisuride—Oedema peripheral—Temozolomide—melanoma	0.00161	0.00818	CcSEcCtD
Lisuride—HTR2B—head—melanoma	0.00159	0.00926	CbGeAlD
Lisuride—Cardiac disorder—Temozolomide—melanoma	0.00152	0.00771	CcSEcCtD
Lisuride—Dizziness—Vemurafenib—melanoma	0.0015	0.00763	CcSEcCtD
Lisuride—HTR2A—eye—melanoma	0.0015	0.00871	CbGeAlD
Lisuride—HTR2A—retina—melanoma	0.00149	0.00863	CbGeAlD
Lisuride—Angiopathy—Temozolomide—melanoma	0.00148	0.00754	CcSEcCtD
Lisuride—Mental disorder—Carmustine—melanoma	0.00148	0.00753	CcSEcCtD
Lisuride—Immune system disorder—Temozolomide—melanoma	0.00148	0.0075	CcSEcCtD
Lisuride—Mediastinal disorder—Temozolomide—melanoma	0.00147	0.00749	CcSEcCtD
Lisuride—Malnutrition—Carmustine—melanoma	0.00147	0.00748	CcSEcCtD
Lisuride—Cough—Bleomycin—melanoma	0.00147	0.00748	CcSEcCtD
Lisuride—Dehydration—Docetaxel—melanoma	0.00146	0.00742	CcSEcCtD
Lisuride—Vomiting—Vemurafenib—melanoma	0.00144	0.00734	CcSEcCtD
Lisuride—Orthostatic hypotension—Docetaxel—melanoma	0.00143	0.00729	CcSEcCtD
Lisuride—Mental disorder—Temozolomide—melanoma	0.00143	0.00728	CcSEcCtD
Lisuride—HTR1A—head—melanoma	0.00143	0.00829	CbGeAlD
Lisuride—Headache—Vemurafenib—melanoma	0.00142	0.00723	CcSEcCtD
Lisuride—Malnutrition—Temozolomide—melanoma	0.00142	0.00723	CcSEcCtD
Lisuride—ADRA2A—mammalian vulva—melanoma	0.0014	0.00813	CbGeAlD
Lisuride—Confusional state—Bleomycin—melanoma	0.00139	0.00705	CcSEcCtD
Lisuride—Infection—Bleomycin—melanoma	0.00137	0.00695	CcSEcCtD
Lisuride—Anorexia—Bleomycin—melanoma	0.00131	0.00667	CcSEcCtD
Lisuride—DRD2—head—melanoma	0.00129	0.00749	CbGeAlD
Lisuride—Vertigo—Temozolomide—melanoma	0.00128	0.0065	CcSEcCtD
Lisuride—Infection—Dactinomycin—melanoma	0.00127	0.00648	CcSEcCtD
Lisuride—Palpitations—Temozolomide—melanoma	0.00126	0.00639	CcSEcCtD
Lisuride—ADRA2C—head—melanoma	0.00125	0.00729	CbGeAlD
Lisuride—Anxiety—Carmustine—melanoma	0.00125	0.00635	CcSEcCtD
Lisuride—Cough—Temozolomide—melanoma	0.00124	0.00631	CcSEcCtD
Lisuride—Weight increased—Docetaxel—melanoma	0.00124	0.00628	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—melanoma	0.00123	0.00624	CcSEcCtD
Lisuride—Dyspnoea—Bleomycin—melanoma	0.00123	0.00624	CcSEcCtD
Lisuride—Anorexia—Dactinomycin—melanoma	0.00122	0.00622	CcSEcCtD
Lisuride—Confusional state—Carmustine—melanoma	0.00121	0.00616	CcSEcCtD
Lisuride—Anxiety—Temozolomide—melanoma	0.00121	0.00613	CcSEcCtD
Lisuride—Decreased appetite—Bleomycin—melanoma	0.0012	0.00608	CcSEcCtD
Lisuride—Infection—Carmustine—melanoma	0.00119	0.00607	CcSEcCtD
Lisuride—Dry mouth—Temozolomide—melanoma	0.00118	0.00602	CcSEcCtD
Lisuride—Tachycardia—Carmustine—melanoma	0.00117	0.00596	CcSEcCtD
Lisuride—Confusional state—Temozolomide—melanoma	0.00117	0.00595	CcSEcCtD
Lisuride—Infection—Temozolomide—melanoma	0.00115	0.00586	CcSEcCtD
Lisuride—Anorexia—Carmustine—melanoma	0.00114	0.00582	CcSEcCtD
Lisuride—Nervous system disorder—Temozolomide—melanoma	0.00114	0.00579	CcSEcCtD
Lisuride—Feeling abnormal—Bleomycin—melanoma	0.00113	0.00576	CcSEcCtD
Lisuride—Hyperhidrosis—Temozolomide—melanoma	0.00112	0.0057	CcSEcCtD
Lisuride—Decreased appetite—Dactinomycin—melanoma	0.00112	0.00567	CcSEcCtD
Lisuride—HTR2B—lymph node—melanoma	0.00112	0.00648	CbGeAlD
Lisuride—Fatigue—Dactinomycin—melanoma	0.00111	0.00562	CcSEcCtD
Lisuride—Anorexia—Temozolomide—melanoma	0.00111	0.00562	CcSEcCtD
Lisuride—Insomnia—Carmustine—melanoma	0.00109	0.00552	CcSEcCtD
Lisuride—Dyspnoea—Carmustine—melanoma	0.00107	0.00544	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—melanoma	0.00107	0.00544	CcSEcCtD
Lisuride—Somnolence—Carmustine—melanoma	0.00107	0.00543	CcSEcCtD
Lisuride—Feeling abnormal—Dactinomycin—melanoma	0.00106	0.00538	CcSEcCtD
Lisuride—Insomnia—Temozolomide—melanoma	0.00105	0.00534	CcSEcCtD
Lisuride—Decreased appetite—Carmustine—melanoma	0.00104	0.00531	CcSEcCtD
Lisuride—Gastrointestinal disorder—Carmustine—melanoma	0.00104	0.00527	CcSEcCtD
Lisuride—Dyspnoea—Temozolomide—melanoma	0.00103	0.00526	CcSEcCtD
Lisuride—Somnolence—Temozolomide—melanoma	0.00103	0.00525	CcSEcCtD
Lisuride—Constipation—Carmustine—melanoma	0.00103	0.00522	CcSEcCtD
Lisuride—Decreased appetite—Temozolomide—melanoma	0.00101	0.00513	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—melanoma	0.00101	0.00513	CcSEcCtD
Lisuride—Gastrointestinal disorder—Temozolomide—melanoma	0.001	0.00509	CcSEcCtD
Lisuride—Fatigue—Temozolomide—melanoma	0.001	0.00509	CcSEcCtD
Lisuride—ADRA2A—head—melanoma	0.001	0.00581	CbGeAlD
Lisuride—Constipation—Temozolomide—melanoma	0.000993	0.00505	CcSEcCtD
Lisuride—Feeling abnormal—Carmustine—melanoma	0.00099	0.00503	CcSEcCtD
Lisuride—Asthenia—Bleomycin—melanoma	0.000987	0.00502	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—melanoma	0.000986	0.00501	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—melanoma	0.000981	0.00499	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—melanoma	0.000979	0.00498	CcSEcCtD
Lisuride—Feeling abnormal—Temozolomide—melanoma	0.000957	0.00486	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—melanoma	0.000952	0.00484	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—melanoma	0.000946	0.00481	CcSEcCtD
Lisuride—Asthenia—Dactinomycin—melanoma	0.000921	0.00468	CcSEcCtD
Lisuride—ADRA2C—lymph node—melanoma	0.000878	0.0051	CbGeAlD
Lisuride—Vomiting—Bleomycin—melanoma	0.000875	0.00445	CcSEcCtD
Lisuride—Asthenia—Carmustine—melanoma	0.000862	0.00438	CcSEcCtD
Lisuride—HTR2A—head—melanoma	0.000851	0.00494	CbGeAlD
Lisuride—Syncope—Docetaxel—melanoma	0.000848	0.00431	CcSEcCtD
Lisuride—Palpitations—Docetaxel—melanoma	0.000836	0.00425	CcSEcCtD
Lisuride—Asthenia—Temozolomide—melanoma	0.000833	0.00423	CcSEcCtD
Lisuride—Cough—Docetaxel—melanoma	0.000825	0.0042	CcSEcCtD
Lisuride—Vomiting—Dactinomycin—melanoma	0.000816	0.00415	CcSEcCtD
Lisuride—Dizziness—Carmustine—melanoma	0.000794	0.00404	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—melanoma	0.000788	0.004	CcSEcCtD
Lisuride—Confusional state—Docetaxel—melanoma	0.000778	0.00396	CcSEcCtD
Lisuride—CYP2D6—head—melanoma	0.000775	0.0045	CbGeAlD
Lisuride—Dizziness—Temozolomide—melanoma	0.000768	0.0039	CcSEcCtD
Lisuride—Infection—Docetaxel—melanoma	0.000767	0.0039	CcSEcCtD
Lisuride—Vomiting—Carmustine—melanoma	0.000764	0.00388	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—melanoma	0.000757	0.00385	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—melanoma	0.000753	0.00383	CcSEcCtD
Lisuride—Headache—Carmustine—melanoma	0.000752	0.00383	CcSEcCtD
Lisuride—Vomiting—Temozolomide—melanoma	0.000738	0.00375	CcSEcCtD
Lisuride—Anorexia—Docetaxel—melanoma	0.000736	0.00374	CcSEcCtD
Lisuride—Headache—Temozolomide—melanoma	0.000727	0.0037	CcSEcCtD
Lisuride—ADRA2A—lymph node—melanoma	0.000701	0.00407	CbGeAlD
Lisuride—Insomnia—Docetaxel—melanoma	0.000698	0.00355	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—melanoma	0.000688	0.0035	CcSEcCtD
Lisuride—Somnolence—Docetaxel—melanoma	0.000686	0.00349	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—melanoma	0.000671	0.00341	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—melanoma	0.000666	0.00339	CcSEcCtD
Lisuride—Fatigue—Docetaxel—melanoma	0.000666	0.00338	CcSEcCtD
Lisuride—Constipation—Docetaxel—melanoma	0.00066	0.00336	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—melanoma	0.000636	0.00323	CcSEcCtD
Lisuride—Asthenia—Docetaxel—melanoma	0.000554	0.00282	CcSEcCtD
Lisuride—Dizziness—Docetaxel—melanoma	0.00051	0.00259	CcSEcCtD
Lisuride—Vomiting—Docetaxel—melanoma	0.000491	0.00249	CcSEcCtD
Lisuride—Headache—Docetaxel—melanoma	0.000484	0.00246	CcSEcCtD
Lisuride—ADRA1B—Signaling Pathways—CTNNB1—melanoma	1.25e-05	2.51e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—melanoma	1.25e-05	2.51e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—melanoma	1.24e-05	2.51e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—melanoma	1.24e-05	2.5e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—melanoma	1.24e-05	2.49e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—melanoma	1.24e-05	2.49e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CDKN1A—melanoma	1.24e-05	2.49e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—melanoma	1.23e-05	2.49e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—melanoma	1.23e-05	2.48e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NFKB1—melanoma	1.23e-05	2.47e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—melanoma	1.23e-05	2.47e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—melanoma	1.22e-05	2.46e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—melanoma	1.22e-05	2.45e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CDKN1A—melanoma	1.22e-05	2.45e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—melanoma	1.22e-05	2.45e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—melanoma	1.22e-05	2.45e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—melanoma	1.22e-05	2.45e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—melanoma	1.21e-05	2.45e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NFKB1—melanoma	1.21e-05	2.43e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—melanoma	1.21e-05	2.43e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—melanoma	1.21e-05	2.43e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK1—melanoma	1.21e-05	2.43e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—melanoma	1.21e-05	2.43e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—melanoma	1.2e-05	2.43e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—melanoma	1.2e-05	2.43e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—melanoma	1.2e-05	2.42e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—melanoma	1.2e-05	2.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	1.2e-05	2.41e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—melanoma	1.2e-05	2.41e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK1—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK1—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—melanoma	1.19e-05	2.4e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—melanoma	1.19e-05	2.39e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—melanoma	1.18e-05	2.39e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—melanoma	1.18e-05	2.38e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—melanoma	1.18e-05	2.38e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—melanoma	1.18e-05	2.38e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—melanoma	1.18e-05	2.38e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—melanoma	1.18e-05	2.37e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—melanoma	1.18e-05	2.37e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—melanoma	1.17e-05	2.36e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—melanoma	1.17e-05	2.36e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—melanoma	1.17e-05	2.35e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—melanoma	1.17e-05	2.35e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—melanoma	1.16e-05	2.34e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—melanoma	1.16e-05	2.34e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—melanoma	1.16e-05	2.34e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—melanoma	1.15e-05	2.32e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—melanoma	1.15e-05	2.31e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—melanoma	1.15e-05	2.31e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—melanoma	1.14e-05	2.3e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—melanoma	1.14e-05	2.3e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—melanoma	1.14e-05	2.3e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—melanoma	1.14e-05	2.29e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—melanoma	1.14e-05	2.29e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PPARG—melanoma	1.14e-05	2.29e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—melanoma	1.14e-05	2.29e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—melanoma	1.14e-05	2.29e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—melanoma	1.13e-05	2.28e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—melanoma	1.13e-05	2.28e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—melanoma	1.13e-05	2.27e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—melanoma	1.13e-05	2.27e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—melanoma	1.12e-05	2.26e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—melanoma	1.12e-05	2.26e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—melanoma	1.12e-05	2.26e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1A—melanoma	1.12e-05	2.26e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—melanoma	1.12e-05	2.26e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—melanoma	1.12e-05	2.25e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—melanoma	1.12e-05	2.25e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—melanoma	1.11e-05	2.25e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NFKB1—melanoma	1.11e-05	2.24e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—melanoma	1.11e-05	2.23e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—melanoma	1.11e-05	2.23e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—melanoma	1.11e-05	2.23e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—melanoma	1.11e-05	2.23e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1A—melanoma	1.1e-05	2.22e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—melanoma	1.1e-05	2.22e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—melanoma	1.1e-05	2.22e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—melanoma	1.1e-05	2.22e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—melanoma	1.1e-05	2.21e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—melanoma	1.1e-05	2.21e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NFKB1—melanoma	1.1e-05	2.21e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—melanoma	1.09e-05	2.2e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—melanoma	1.09e-05	2.2e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—melanoma	1.09e-05	2.2e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—melanoma	1.09e-05	2.19e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—melanoma	1.09e-05	2.19e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—melanoma	1.08e-05	2.18e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK1—melanoma	1.08e-05	2.18e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—melanoma	1.08e-05	2.18e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—melanoma	1.08e-05	2.18e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—melanoma	1.08e-05	2.17e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—melanoma	1.08e-05	2.17e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—melanoma	1.08e-05	2.17e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK1—melanoma	1.07e-05	2.16e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—melanoma	1.07e-05	2.16e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—melanoma	1.07e-05	2.16e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—melanoma	1.07e-05	2.16e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—melanoma	1.07e-05	2.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—melanoma	1.07e-05	2.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—melanoma	1.07e-05	2.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—melanoma	1.06e-05	2.14e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—melanoma	1.06e-05	2.13e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—melanoma	1.05e-05	2.12e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—melanoma	1.05e-05	2.12e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—melanoma	1.05e-05	2.11e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—melanoma	1.05e-05	2.11e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—melanoma	1.04e-05	2.1e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—melanoma	1.04e-05	2.09e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—melanoma	1.04e-05	2.09e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—melanoma	1.04e-05	2.09e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK1—melanoma	1.04e-05	2.09e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—melanoma	1.04e-05	2.09e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—melanoma	1.03e-05	2.08e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—melanoma	1.03e-05	2.08e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK1—melanoma	1.03e-05	2.08e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—melanoma	1.03e-05	2.08e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—melanoma	1.03e-05	2.07e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—melanoma	1.03e-05	2.07e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—melanoma	1.03e-05	2.07e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—melanoma	1.03e-05	2.07e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—melanoma	1.02e-05	2.06e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—melanoma	1.02e-05	2.06e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—melanoma	1.01e-05	2.04e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—melanoma	1.01e-05	2.04e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—melanoma	1.01e-05	2.04e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—melanoma	1.01e-05	2.03e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—melanoma	1.01e-05	2.03e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1A—melanoma	1e-05	2.02e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK1—melanoma	1e-05	2.02e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—melanoma	1e-05	2.02e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—melanoma	1e-05	2.02e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—melanoma	1e-05	2.02e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—melanoma	9.99e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—melanoma	9.99e-06	2.01e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—melanoma	9.99e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NFKB1—melanoma	9.98e-06	2.01e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—melanoma	9.95e-06	2e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK1—melanoma	9.88e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—melanoma	9.88e-06	1.99e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—melanoma	9.86e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—melanoma	9.86e-06	1.98e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PRKCA—melanoma	9.85e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—melanoma	9.83e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—melanoma	9.83e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—melanoma	9.8e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—melanoma	9.78e-06	1.97e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ERCC2—melanoma	9.77e-06	1.97e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—melanoma	9.75e-06	1.96e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—melanoma	9.68e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—melanoma	9.65e-06	1.94e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—melanoma	9.57e-06	1.93e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—melanoma	9.55e-06	1.92e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—melanoma	9.55e-06	1.92e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—melanoma	9.5e-06	1.91e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—melanoma	9.48e-06	1.91e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—melanoma	9.42e-06	1.9e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—melanoma	9.41e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—melanoma	9.33e-06	1.88e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—melanoma	9.32e-06	1.88e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—melanoma	9.31e-06	1.87e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—melanoma	9.27e-06	1.87e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—melanoma	9.16e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—melanoma	9.14e-06	1.84e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—melanoma	9.14e-06	1.84e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK1—melanoma	9.11e-06	1.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—melanoma	9.1e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—melanoma	9.1e-06	1.83e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—melanoma	9.07e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—melanoma	9.06e-06	1.82e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—melanoma	9.04e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—melanoma	9.02e-06	1.82e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—melanoma	9e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—melanoma	8.97e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK1—melanoma	8.96e-06	1.8e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—melanoma	8.96e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—melanoma	8.96e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—melanoma	8.95e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—melanoma	8.95e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—melanoma	8.71e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—melanoma	8.71e-06	1.75e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—melanoma	8.71e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—melanoma	8.66e-06	1.74e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—melanoma	8.63e-06	1.74e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—melanoma	8.6e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—melanoma	8.57e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—melanoma	8.57e-06	1.73e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—melanoma	8.55e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—melanoma	8.51e-06	1.71e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—melanoma	8.46e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—melanoma	8.46e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—melanoma	8.44e-06	1.7e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—melanoma	8.44e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—melanoma	8.42e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—melanoma	8.33e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—melanoma	8.33e-06	1.68e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—melanoma	8.33e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—melanoma	8.29e-06	1.67e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—melanoma	8.28e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—melanoma	8.26e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK1—melanoma	8.15e-06	1.64e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—melanoma	8.15e-06	1.64e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—melanoma	8.06e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—melanoma	7.97e-06	1.6e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—melanoma	7.93e-06	1.6e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—melanoma	7.93e-06	1.6e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—melanoma	7.9e-06	1.59e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—melanoma	7.81e-06	1.57e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—melanoma	7.78e-06	1.57e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—melanoma	7.72e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—melanoma	7.71e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—melanoma	7.7e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—melanoma	7.69e-06	1.55e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—melanoma	7.64e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—melanoma	7.62e-06	1.53e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—melanoma	7.59e-06	1.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—melanoma	7.52e-06	1.51e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPARG—melanoma	7.45e-06	1.5e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—melanoma	7.35e-06	1.48e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—melanoma	7.31e-06	1.47e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—melanoma	7.31e-06	1.47e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—melanoma	7.19e-06	1.45e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—melanoma	7.11e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—melanoma	7.07e-06	1.42e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—melanoma	7e-06	1.41e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—melanoma	7e-06	1.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—melanoma	6.91e-06	1.39e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—melanoma	6.88e-06	1.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—melanoma	6.84e-06	1.38e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—melanoma	6.78e-06	1.37e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—melanoma	6.7e-06	1.35e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—melanoma	6.54e-06	1.32e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—melanoma	6.46e-06	1.3e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—melanoma	6.35e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—melanoma	6.26e-06	1.26e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—melanoma	5.91e-06	1.19e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—melanoma	5.86e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—melanoma	5.78e-06	1.16e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—melanoma	5.51e-06	1.11e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—melanoma	5.11e-06	1.03e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—melanoma	4.5e-06	9.07e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—melanoma	3.6e-06	7.26e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—melanoma	2.94e-06	5.93e-06	CbGpPWpGaD
